New Year, New Biopharma: Game Changers We're Betting On In 2026

2026 is shaping up to be a pivotal year for biopharma, with digital transformation, regulatory shifts, and economic pressures driving change. Expect automation and AI to redefine manufacturing, enabling smarter, more connected processes and real-time quality control. Regulators are preparing for a surge in generics and biosimilars, leaning on advanced analytics and AI to streamline approvals. Meanwhile, economic uncertainty is accelerating process intensification, pushing manufacturers toward smaller, more agile production footprints that also support sustainability goals. On the clinical front, breakthroughs in oncology, cell therapies, and gene editing promise to reshape treatment paradigms. Collaboration across the value chain will be critical to turning these opportunities into reality.

Explore the trends and challenges that could make 2026 a transformative year for biopharma.